

IACFS/ME

2022 Conference Highlights

Lily Chu, MD, MSHS
iacfsmeorg@gmail.com
August 26, 2022

Conference Overview

- * 3.5 days, virtual
- * 300+ attendees
- * 58 speakers and 20+ posters
- * 30% of attendees from outside US (Europe, Australia and Japan)
- * 20% students, trainees, early career professionals

Three Themes & Questions


- * Infection: EBV
- * Immune exhaustion
- * Imbalance in autonomic nervous system



- * What is the context for this study?
- * What question/ issue is it trying to address?
- * How might results advance understanding or affect care?

Infection: EBV life cycle

Fig. 1



Current tests & antivirals target these phases

BUT what if this picture is wrong?

May explain “normal” tests & ineffective treatments

Infection: EBV abortive lytic state



Cox, Brandon S., et al. "EBV/HHV-6A dUTPases Contribute to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Pathophysiology by Enhancing T_{FH} Cell Differentiation and Extrafollicular Activities." *JCI Insight*, vol. 7, no. 11, June 2022. [insight.jci.org](https://doi.org/10.1172/jci.insight.158193), <https://doi.org/10.1172/jci.insight.158193>.

- ★ Intermediate between latent and lytic
- ★ EBV dUTPase: virus replication & ? immune dysfunction
- ★ EBV/HHV-6 dUTPase Ab: 53% ME/CFS vs. 29% HC


Do dUTPases cause immune dysfunction?
How do they cause immune dysfunction?

67% vs. 14%
above normal, $p < 0.001$

3809 pg/mL \pm 500.8
vs. 5156 pg/mL \pm 585.1,
 $p < 0.01$



Naive CD4 cells mature when exposed to ME/CFS sera



- * dUTPase Ab+ ME/CFS sera has Activin A, dUTPase
- * FST inhibits Activin A
- * Activin A is sufficient to stimulate CD4 T-cell maturation
- * Also, despite maturation, decreased function

Infection: what's possible?

- * Re-define “active” EBV infection, leading to new tests
- * Development of treatment targeting abortive lytic states

Immune exhaustion: CD8 T-cells


- * If chronic viral infection = exhausted immune system?
- * CD8 T-cells target viruses (& cancerous cells)
- * Changes with exhaustion:
 - ✓energy production/ use
 - ✓mitochondria electrical signals

Are there other changes that support exhaustion?

What can be done?

Immune exhaustion: cell markers

J. Maya, Cornell



Immune exhaustion: function decreased

L. Selin & A. Gil, Univ of Massachusetts

% of CD8 T-cells producing cytokines after stimulation (p<0.01)

	Healthy	Long COVID	ME/CFS
IFN-gamma	30%	6%	6%
TNF-alpha	33%	10%	8%
Inspiritol cases		N= 5	N=4
After Inspiritol + ? antiviral		Improved sx. Increased function	Improved sx. Increased function

Inspiritol: antioxidant/-inflammation/-bacterial/-viral


Inhaled (COPD, Asthma)

Minimal side effects (cough)

Immune exhaustion: what's possible?

- * Immune exhaustion as chicken instead of the egg
- * Markers and/or function to help diagnose ME/CFS
- * Improve T-cell exhaustion = may treat illness even if “chicken” unknown?
 - a. Checkpoint inhibitors -block surface markers
 - b. Gene editing: knock out/ silence genes associated with exhaustion
- ★ Synergy with antivirals? other meds?


Imbalance: what is the ANS?




Imbalance: sympathetic predominance?

- * Many ME/CFS symptoms suggest ANS dysfunction
- * Objective finding examples:
 - Unrefreshing sleep linked to increased symp activity
 - Autoantibodies to adrenergic/ muscarinic receptors

Parasympathetic




Sympathetic



What is a stellate ganglion block (SGB)?

D. Duricka and L. Liu, Neuroversion



Standard procedure approved for pain syndromes, excess sweating, Raynauds

Block sympathetic signalling via stellate ganglia

SGB & ME/CFS: 2/ 5 cases

	Patient #1	Patient # 2
Age/ duration	62 / 18 yrs.	52/ 32 yrs.
Onset	Estradiol injection	Mono/ Hep A hospitalization
Symptoms	PEM/ cognitive issues	PEM/ body pain
Other diagnoses	Ind	Ind +Asthma, allergies, MCAS
Injection pattern	10 sets over 21 days	8 sets over 4 months
Improved symptoms	Multiple	Multiple + Co-morbid
Duration of improvement	At least 9 months	6 weeks
Outcome	95% pre-illness No further treatment	Relapsed with surgery; resumed treatment

Caution: not a trial, small sample size, SGB risks

What is transcutaneous auricular vagus nerve stimulation (taVNS)?

N. Clague-Baker, University of Liverpool, UK

Originally for treatment-resistant seizures/ depression
Stimulates parasympathetic signalling via vagus nerve



taVNS and ME/CFS: feasibility

- ★ 116 people, 75% Europeans, 50% sick 10+ year
- ★ Only 10% used 1+ year

- ★ 70% continued, 30% stopped
- ★ Main pros: 40% report improved PEM, cognition
- ★ Main cons: 15% headache, 10% skin irritation

Caution: costs, model, adjustment time, not = to implant

Imbalance: what's next?

- * Encourage exploration of ANS role
- * Need clinical trials for validation, refinement
- * Use as diagnostic test to target treatment

Conclusion

- * Studies replicating and/or reinforcing other studies
- * Tests & treatments can be designed/ assessed now even if exact cause(s) and mechanism not yet known

To purchase video recordings & read summaries:
Visit www.iacfsme.org